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ABSTRACT 
 
Monoclonal antibodies have proven to be an extremely successful class of protein 
therapeutics. Monoclonal antibodies and other biopharmaceutical products used in humans, are 
required to meet strict purity standards.  Cation-exchange (CIEx) chromatography has become a 
staple of monoclonal antibody purification platforms. In this project, an experimental 
chromatography resin specifically designed to be operated in flow-through mode and replace 
traditional CIEx during monoclonal antibody polishing has been characterized. The results show 
that this new resin can achieve higher loading capacities and reduced buffer consumption, 
resulting in improved process economics, while being an effective replacement for currently 
available CIEx resins that are designed to be operated in bind-and-elute mode.  
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BACKGROUND 
Monoclonal Antibodies 
Monoclonal antibodies (mAbs) are generated in the laboratory by using a single clone of 
a B cell. B cells are the cells within the immune system that produce antibodies. Antibodies, 
which are also referred to as immunoglobulins (Igs), are proteins which assist the immune 
system in identifying foreign agents, such as viruses and/or bacteria, within the body.  
Immunoglobin gamma (IgG) is the most abundant type of antibody, and is present in blood and 
other bodily fluids. Antibodies function by binding to a foreign invader, also known as an 
antigen, so the antigen is recognized as being foreign and it is trigged to be eliminated from the 
body. Unlike polyclonal antibodies which bind to a variety of antigens, mAbs can bind very 
specifically to one target antigen. (Longe, 2010) 
The basic molecular structure of most antibodies is “Y” shaped, and consists of variable 
and constant regions (Figure 1). The variable regions vary in sequence and structure, which 
allows them to develop binding specificities against a wide range of antigens. The constant 
region is conserved among antibodies, and is responsible for interacting with the effector system 
and triggering elimination of the antigen from the body. Researchers have taken advantage of 
mAb’s ability to recognize various targets with high specificity to produce many important 
therapeutic and diagnostic tools.  (Nelson PN, 2000) 
 
 
 
 
Figure 1: Schematic representation of an antibody molecule 
highlighting the “Y” shaped structure (Nelson PN, 2000) 
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Monoclonal Antibodies as Therapeutic Drugs 
Monoclonal antibodies are useful within laboratory research and as pharmaceutical 
therapeutics to treat a wide variety of diseases and illnesses. “By 2009, forty-six different 
monoclonal antibodies had been licensed for the treatment of a variety of diseases, including 
cancer, asthma, and rheumatoid arthritis, and for use in transplantation.” (Wood, 2010) 
Depending on the required therapeutic effect, mAbs can act by blocking or neutralizing a 
receptor, or they can take an active role by targeting an effector function. 
One successful therapeutic mAb, Herceptin, is used to treat a specific form of breast 
cancer. Herceptin binds to Her-2, a growth receptor found on the surface of breast cancer cells. 
Her-2 is responsible for sending signals towards the inside of breast cancer cells, requesting the 
cells to divide and grow. Herceptin slows this process by binding to Her-2 and inhibiting the cell 
signals, therefore, slowing down the cell division process.  
 Monoclonal antibodies can also work to fight cancers by enabling the immune system to 
attack and eliminate the cancerous cells. This is the case for antibodies such as Rituximab, which 
are used to treat leukemia. These antibodies bind to leukemia cancer cells and then signal the 
immune system to kill the cells. Monoclonal antibodies are also useful when it comes to 
suppressing the immune system. Suppressing the immune system can have therapeutic value 
during allergic reactions and transplantation procedures. (Wood, 2010)  
As a result of their proven therapeutic and diagnostic applications, mAbs have gained a 
huge amount attention and investment from researchers and businesses worldwide. 
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Forecasted Economic Outlook of Monoclonal Antibodies 
 Monoclonal antibodies are becoming a staple of the pharmaceutical industry. In terms of 
the growing market for protein-based therapeutics, mAbs are market leaders based on volume 
sales (Gottschalk, 2009).  The ten mAbs currently utilized for cancer therapy collectively 
generated US$17 billion in revenue in 2009. Evaluate Pharma estimates that by 2016, products 
made from monoclonal antibodies will represent 11 of the top 50 selling therapeutic products in 
the world, 6 of them being the top 10 selling products. (Becker, 2010) By the end of 2011, it had 
been estimated that monoclonal antibodies alone generated revenue of about US$48 billion. 
(Becker, 2010) 
It is forecasted that mAbs will play a major role in the future of disease treatment; 
consequently, there is currently a significant amount of resources being expended on the research 
and manufacturing capabilities of mAbs. As a result, it is of importance for scientists to ensure 
mAbs can be safely and economically manufactured, and distributed as therapeutics to patients. 
 
Impurity Clearance of Monoclonal Antibodies 
  Monoclonal antibodies have proven to be an extremely successful class of protein 
therapeutics, and when used as human therapeutics, they along with other biopharmaceutical 
products, are required to meet strict regulatory and purity standards. Commercial production of 
mAbs is divided into two major steps, each is comprised of smaller unit operations to complete 
the process. First, animal cells expressing an antibody are grown in a stirred bioreactor 
containing a nutrient rich liquid medium. Once the antibody reaches a target titer in the medium, 
it needs to be separated from the cells and harvested from the bioreactor. The aforementioned is 
commonly referred to as upstream processing. The antibody is then purified by separating the 
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target molecule from various soluble impurities, generally by means of filtration and 
chromatography, and this is referred to as downstream processing. Table 1 displays the major 
impurities requiring removal validation, and some of the characterization/quantification 
techniques used during downstream processing. 
 
Impurity/Characterization Detection Method 
Host Cell Proteins (HCP) Chinese Hamster Ovary (CHO) Host Cell 
Proteins ELISA 
Leached Protein-A Protein-A ELISA 
Aggregates Size Exclusion High Performance Liquid 
Chromatography 
DNA QPCR, PicoGreen Assay  
Protein Concentration Ultra Violet (UV) Absorbance 
Viruses QPCR, Infectivity Assay 
Table 1: During the downstream process, various bio-analytical tests are 
performed to determine the purity and characterization of the monoclonal 
antibodies during the manufacturing process. 
 
Importance of Aggregate and Protein A Clearance from Monoclonal Antibodies 
 Two related impurities which must be sufficiently removed from monoclonal antibodies 
during downstream processing are aggregates and leached Protein-A. These must be removed 
from the mAbs because of their immunogenicity (Farhner, 2001), and can be sufficiently cleared 
by employing cation-exchange chromatography (Gottschalk, 2009). 
Most mAb preparations start out with some level of aggregates, typically 1-15%, and 
efforts need to be made to reduce the level in the final product per FDA guidance (FDA, 2013). 
Typical target levels for the final product are less than 0.5%, as protein aggregates are known to 
cause negative immune responses within patients treated with antibodies which contain high 
levels of protein aggregates. As a result of there being many different factors involved in 
immunogenicity, it has been difficult for researchers to pinpoint the exact linkage between 
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aggregates and immunogenicity. Recently, a few hypotheses have been proposed to explain the 
alteration of immunogenicity of protein aggregates, including their:  “(1) enhanced 
immunogenicity by oxidation-induced structural change; (2) enhanced immunogenicity by 
formation of repetitive structures in oxidation-derived aggregates; and (3) reduced 
immunogenicity by alteration or even loss of immunogenic epitopes in protein aggregates after 
different treatments” (Wang, 2012). However, it is understood that because the aggregates have 
similar sequences as the monomer they can also cause the patient to have an immune response 
towards the therapeutic monomer thus causing neutralizing antibodies to decrease the efficacy of 
the monomer overtime (De Groot, 2007).  
Protein-A, a bacterial cell wall protein, is immobilized onto a solid media, and is often 
used as the first step of purification of mAbs as an affinity chromatography capture step. Because 
of its high specificity for antibodies, the Protein-A chromatography step results in >95% purity 
of the target molecule in one step. However, during this process, some of the Protein-A comes 
off of the column and into the antibody sample. This “leached” Protein-A can be potentially 
immunogenic, and can have other physiological consequences, therefore, it is also required to be 
removed during downstream processing of the monoclonal antibodies. (Farhner, 2001) 
Much research has been conducted on how to most effectively produce and manufacture 
an extremely pure, high yield of mAbs. After years of types of research and investments into 
facilities, column chromatography has become the preferred platform for maintaining high yields 
of product and to remove impurities from during downstream processing (Gottschalk, 2009). 
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Column Chromatography 
 In the biotechnology industry, column chromatography is the most utilized technique to 
separate impurities from their target molecules. Chromatography columns are cylindrical in 
shape, and can be constructed from glass, stainless steel, or acrylic. There are multiple different 
types of column chromatography currently utilized, some of which include: affinity, anion/cation 
exchange, mixed-mode, gel filtration (size exclusion), hydrophobic interaction, and reverse 
phase. Chromatography columns are most often packed with resin beads, also referred to as 
“media.” The media can capture the impurities and allow the target molecules to flow-through 
(flow-through mode), or can capture the target molecule and differentially bind the impurities 
(bind-and-elute mode).  Figure 2 shows a chromatography schematic to visualize flow of the 
target molecules through resin beads in a chromatography column. (Fetterolf, 2009) 
 
 
 
 
 
 
 
 
Figure 2: Diagram of the flow in a packed  
chromatography column. (Fetterolf, 2009) 
 
 Column chromatography, like most other laboratory procedures, is defined by a step-by-
step procedure. The order of the process run in bind-and-elute mode is: (1) Equilibration, (2) 
Loading, (3) Washing, (4) Elution, (5) Strip and Cleaning-in-place (CIP). In equilibration, a 
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buffer solution rinsed through the column for the resin and the entire system itself to be at the 
desired pH, conductivity, and temperature. Once the column is equilibrated, the product is ready 
to be loaded into the column. In “bind-and-elute” chromatography, the target molecules bind to 
the resin, and the impurities either flow through the column or are retained more strongly than 
the target molecule and remain on the column after the product is eluted. The goal of bind-and-
elute is to have virtually none of the target molecules in the “flow through” or remaining on the 
column after elution.  
One of the main factors to be considered during any column chromatography procedure 
is flow rate. The higher the flow rate, the less probable the target molecules will bind to the resin 
due to decreased contact time, also referred to as “residence time.” During the wash phase, which 
is preparation for the elution phase, the same buffer solution used during the equilibration step is 
flowed through the column to rinse away any loose impurities which may still be present in the 
column. The elution step is when the target molecules are released from the resin and are 
collected to form the final product pool. In ion exchange chromatography, this step is achieved 
by either increasing the salt concentration, or causing a shift in pH of the column by eluting the 
column with a buffer with a higher salt concentration or pH than the previously used buffer. In 
terms of the strip and CIP, an extreme elution buffer, with a high salt concentration is used to 
remove any leftover target molecules still bound to the resin via ionic interactions, and the CIP is 
typically performed with a caustic wash such as 0.5 N NaOH.  The caustic wash can also 
function as a column sanitization. This is an important step because resin is expensive and 
columns are often re-used multiple times to improve process economics; therefore, it is pertinent 
to make sure any remaining material is removed before the next cycle of materials. (Fetterolf, 
2009) 
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 Despite the numerous types of current column chromatography methods and platform 
purification processes, bioprocess developers are always looking for new technologies to 
improve the robustness and economics of mAb production.  
 
Traditional 3-Step Chromatography Process 
The effective purification of mAbs can require three or more sequential chromatography 
steps. A commonly reported chromatography series includes: Protein-A affinity chromatography, 
cation-exchange chromatography, and anion-exchange chromatography (Farhner, 2001). 
Protein-A Affinity Chromatography uses porous beads with immobilized Protein-A. As 
discussed previously, Protein-A is a bacterial cell wall protein which specifically binds to 
antibodies, allowing impurities to flow through. An example of a resin that is used for Protein-A 
chromatography is ProSep® Ultra Plus media (EMD Millipore). The importance of this Protein- 
A step in a mAb purification is it concentrates the product, and removes cell proteins, DNA, and 
media components. This step alone achieves >95% purity, however, it does not remove product 
related aggregates, and it adds a new, process related impurity, leached Protein-A, into the feed. 
Cation-exchange uses beads with negatively charged sites that bind molecules that are 
positively charged. An example of such beads is Fractogel® SO3 media.  Figure 3 shows a SEM 
of negatively charged Fractogel® beads (Staby, Jacobsen, Hansen, Bruus, & Jensen, 2006). This 
step is used to remove impurities such as aggregates and Leached Protein-A. Typically, cation-
exchange chromatography is operated in bind-and-elute mode, and requires increased 
conductivity to elute the target molecule. The resulting high conductivity product pool requires 
dilution back to low conductivity or the use of salt tolerant chromatography for the next step, 
anion-exchange chromatography, to be effective. This MQP project is based on exploring the 
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utility of a novel cation-exchange resin with a proprietary surface modification that can be 
operated in flow-through mode without an increase in conductivity.           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Scanning electron microscope photograph of the surface of 
Fractogel
®
 bead. (Staby, Jacobsen, Hansen, Bruus, & Jensen, 2006) 
 
Anion-exchange is often the last chromatography step of the three-step process; this step 
uses a flow-through method. Anion-exchange uses positively charged sites to bind negatively 
charged solutes. Anion-exchange uses porous beads or membranes with positively charged sites 
such as Fractogel® TMAE media and ChromaSorb™ membrane adsorber (EMD Millipore). 
Fractogel® TMAE media are anion-exchange beads with positively charged sites that bind 
molecules that are negatively charged, and ChromaSorb™ membrane adsorber is a salt-tolerant 
anion exchange membrane absorber. In this flow-through method, the feed is flowed through the 
resin, the impurities bind to the resin, and the purified product flows through the resin.  This step 
removes DNA, viruses, and residual host cell protein to produce the final product. 
 
Traditional Bind-and-Elute Cation-Exchange Chromatography 
 As discussed previously, in cation-exchange chromatography, the chromatography media 
used in the chromatography column has negatively charged ligands on the surface of the resin. 
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These negatively charged ligands capture the positively charged target molecules and allows for 
the negatively charged impurities to flow through the column. Once the negatively charged 
impurities flow through the column and the positively charged target molecules are captured on 
the negatively charged resin, a buffer with increased sodium chloride is used to create a salt 
gradient during the elution phase. The positively charged sodium competes with the target 
molecule for negative sites and on the resin, and the target molecules are dissociated and flow 
into the elution pool. The resulting pool has a high conductivity, which requires a dilution or 
diafiltration before moving onto the next step, anion-exchange chromatography, which requires 
low conductivity. The dilution step can be problematic especially for large facilities that have 
installed intermediate tanks of a fixed size. Also water-for-injection which is used for the 
dilution can be very expensive, and the increase in volume adds time and labor to the process. 
(Zhou, 2007) 
 In a new flow-through chromatography method that has been designed (discussed below), 
there is no need for an increased conductivity. Therefore, there is no need for a dilution step 
between the cation-exchange step and the anion-exchange step. 
 
Novel Flow-Through Chromatography 
In a new 3-step process designed by scientists at EMD Millipore, a flow through 
chromatography resin and method has been developed. In order to achieve this novel flow-
through process, specially designed beads, with a proprietary ligand capable of retaining 
aggregates and leached protein-A impurities, are used as the chromatography media. While these 
impurities bind to the beads, the purified protein product is able to flow through the beads and 
collect for subsequent purification. In this new process the traditional bind-and-elute cation 
15 
 
exchange step is replaced with a step that achieves several times the resin loading capacity with a 
resulting low conductivity pool. This results in improved process economics, and circumvents a 
costly and sometimes facility-constrained dilution step.  
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PROJECT PURPOSE 
 
 
This MQP project worked towards characterizing an experimental chromatography resin 
that is specifically designed to be operated in flow-through mode during mAb polishing. The 
data indicate that this new resin can be an effective replacement for currently available cation-
exchange resins designed to be operated in bind-and-elute mode. 
 
Goal and Scope:  
 
Characterize a novel EMD Millipore chromatography resin, and explore the utility of this new 
tool in mAb purification.  
 
Objectives: 
1. Gain a background understanding of monoclonal antibody purification. 
2. Use a Chromatography Workstation to characterize a library of resin prototypes and 
determine optimal resin design for mAb purification.  
3. Explore this new resin’s effectiveness in replacing a traditional cation-exchange resin 
towards a completely flow-through mAb polishing platform. 
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METHODS AND MATERIALS 
 
General Overview of the Experimental Process 
1. Obtain clarified cell culture medium containing mAbA. 
2. Generate Protein-A Pool. 
3. Screen various prototype flow-through resins. 
4. Pack columns with prototype flow-through resins and load them onto an AKTA explorer. 
Program the AKTA to run method as outlined in Table 2. 
5. Run the method to bind the impurities, flow through the purified product, and elute out 
the impurities at the strip phase while collecting fractions. 
6. Analyze collected fractions for aggregate removal using Size Exclusion HPLC. 
7. Measure protein concentrations of each fraction using NanoDrop. 
8. Perform three step Chromatography purification process using new flow-through resin as 
the intermediate polishing step and Fractogel® TMAE media and/or ChromaSorb™ 
adsorber as the final anion-exchange step. 
9. Analyze fractions for impurity (Host Cell Protein, Leached Protein-A, DNA, Aggregates) 
clearance. 
 
Detailed Descriptions of Experimental Processes 
 
A clarified cell culture expressing a test monoclonal antibody (MAbA) was obtained 
using a proprietary process. The MAbA was partially purified with Protein-A affinity 
chromatography to produce an intermediate step pool. The protein concentration of pool was 
measured by a 2000c NanoDrop (Thermo SCIENTIFIC). The NanoDrop software was then used 
to calculate the protein concentration of the Protein-A pool. 
 A library of experimental flow-through chromatography matrices were prepared by a 
proprietary method. The matrices all had various iterations of surface chemistry designed to 
interact with proteins more or less strongly. The types of matrices which were used included both 
membranes and resin beads.  
All of the flow-through chromatography experiments were performed on an AKTA 
Explorer (GE Healthcare) using 50 mM Sodium Acetate at pH 5 for the equilibration buffer, 50 
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mM Sodium Acetate at pH 5 as the loading buffer, using the equilibration buffer for the wash 
step, using equilibration buffer plus 300 mM NaCl for the strip buffer, 0.5M NaOH as the 
cleaning buffer, and then a final equilibration wash with the equilibration buffer (Table 2). For 
the resin bead experiments, glass columns with internal diameters of 6.6mm were packed to a 
bed height of 3cm, which provided total volumes of 1mL of resins and then loaded onto the 
AKTA Explorer. For the membrane experiments, 3, 4, and 5 layers of membranes were loaded in 
membrane devices and then loaded onto the AKTA explorer. The feed MAbA Protein-A pool 
was loaded into a super loop on the AKTA Explorer. The specific method for each experiment 
was programmed onto the AKTA software (Unicorn). Once a method was begun, the AKTA 
pumped cell culture through the columns or membranes to bind the impurities, flow through the 
purified product, and elute out the impurities at the regeneration phase. The end products were 
collected as 2 mL fractions of purified MAbA into a 96-well plate. The output of the software at 
the end of each experiment was a detailed chromatogram for each individual experiment. 
 
Process Step Buffer Residence Time 
(min) 
Duration (Column 
Vol.) 
Equilibration (EQ) 50 mM Sodium 
Acetate, pH 5 
3 8 
Loading EQ buffer + 
MAb 
3 mL = 100, Load density 
= 400 mg/mL 
Wash EQ 3 10 
Strip EQ + 300 mM 
NaCl 
3 5 
Clean-in-place 0.5 M NaOH 3 5 
EQ EQ 3 5 
Table 2: Example of method used for AKTA Explorer cation-exchange chromatography 
experiments. *NOTE: different runs had varying method conditions. 
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After these 2mL fractions were collected from the AKTA Explorer, a chromatogram was 
output by the AKTA software, a sample of such a chromatogram can be viewed in Figure 4. 
 
 
 
 
 
 
 
 
Figure 4: Sample chromatogram run on the AKTA Explorer (GE Healthcare), using the 
new EMD Millipore flow-through resin.  
 
The plate was then placed onto the HPLC (Gilson). The method was run on the HPLC 
software in order to analyze aggregate removal in each sample. During this method, the liquid 
handler would insert itself into an individual well of the 96-well plate and take 20 uL of the 
sample and send it through the GFC (HPLC) column (SEC HPLC TSKsw3000). The output of 
the software at the end of each experiment was a chromatogram which displayed peaks which 
referred to the percent of aggregate in the sample vs. the percent of monomers in each fraction, a 
s seen in Figure 5.  
  
Flow-through 
fractions 
Salt Strip 
NaOH Clean 
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Figure 5: Analysis of Fractions for Aggregates using Size Exclusion HPLC.  A: Protein-
A Pool;  B: CIEx Flow-Through,  C: CIEx Strip. 
 
The protein concentrations of each of these samples were measured using a 2000c 
NanoDrop. 2 uL of each sample was dropped onto the NanoDrop platform using a 10 uL pipette. 
The NanoDrop software was then used to calculate the protein concentration of each individual 
fraction. 
The samples of purified MAbA with a low aggregate percentage were then pooled 
together. This pool was then loaded onto the super loop on the AKTA. Fractogel
®
 TMAE  was 
loaded into a column and a ChromaSorb
TM
 membrane was loaded onto the AKTA. In the anion-
exchange step of the three-step protein purification chromatography process, the pool was sent 
through the Fractogel
® 
TMAE column and/or the ChromaSorb
TM
 membrane in order to further 
purify the samples.  These final samples were then assayed using validated protocols. The assays 
used include: 
 Aggregates: Size Exclusion Chromatography (SEC) HPLC 
o See protocol mentioned above; same steps used. 
 Protein Concentration: NanoDrop Absorbance 
o See protocol mentioned above; same steps used. 
 HCP: CHO Host Cell Proteins 3rd Generation ELISA (specifically used for Chinese 
Hamster Ovary MAbs) 
 Leached Protein A: Protein A ELISA 
 DNA: PicoGreen Assay 
 Non-Reducing SDS-PAGE gel 
B. 
C. 
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RESULTS 
 
 We received over 20 various prototypes of resin with varying levels of surface 
modification, and evaluated them for aggregate removal from a test mAb preparation. The 
prototypes were loaded onto the AKTA in glass columns with an internal diameter of 6.6mm, a 
bed height of 3cm and a total volume of 1mL. A mAb solution of 13.5 mg/mL with 2.0 % 
aggregates was flowed through the resin beads at 3 minute residence time, and various assays 
were used to analyze the efficiency of the resin beads. Figure 6 shows four of the prototypes and 
their ability to separate aggregates. We concluded that prototypes #4 (purple dotted curve) had 
the best ability to separate monomer from aggregates in flow-through mode so we used this resin 
for the remainder of the experiments going forward.  
 
 
 
 
 
 
 
 
 
 
Figure 6 shows four of the prototypes tested and their ability to separate aggregates. 
Prototype #4 (purple dotted curve) displayed the best ability to separate aggregate from 
monomer which is determined by the late aggregate break-through (right side) of the 
aggregates at 150 mg/mL.  
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 To determine the effect of residence time (flow rate) on the ability for resin prototype #4 
we tested the resin at 1, 3, and 6 minute residence time (Figure 7). For example the shorter the 
residence time, the less time it takes to exchange a column volume. Since aggregates are large 
molecules, we were concerned with a dramatic drop off of capacity at short residence time (faster 
flow rates) because the molecule would have less time to access the internal surface area of the 
bead. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 shows the impact of applying the sample at 1, 3, and 6 minute residence times. 
This shows that there is not a large decrease in dynamic binding capacity for aggregates 
between 1 and 6 minute residence time. This is important as we begin to assess the 
industrial applications of this technology because processing time is an important factor 
that contributes to process economics.  
 
 To evaluate the applicability of resin beads as a chromatography medium for the 3-step 
chromatography purification template, we tested a full purification train and applied the 
appropriate assays. To begin the experiment we generated a Protein-A pool from a cell culture 
23 
 
containing a monoclonal antibody. The protein A pool had 5.4% aggregates determined by 
(SEC) HPLC. Next, we adjusted the pH of the protein-A pool to pH 5.0 and performed the new 
flow-through process for removal of aggregates. Finally, the last step consisted of either 
ChromaSorb
TM 
 membrane adsorber or Fractogel
®
 chromatography resin. The results are shown 
below on Table 3. Also, Figure 8 shows a non-reducing SDS-PAGE gel for the three step 
process.  
 
Table 3 shows a three step process of purifying a monoclonal antibody from crude cell 
culture. This process includes a protein-A step, a novel flow-through process to remove 
aggregates, and one of two separate anion-exchange flow-through steps.  
 
 
 
 
 
 
 
 
 
Protein A Pool   Starting 5.4 %  Starting 251 (ppm) 24000 (ppm) 
Protein Load 
Density (mg 
protein/mL resin) 
% Protein 
Recovery 
% Aggregates 
6min  
[LProtein A] 
(ppm) 
[HCP] (ppm) 
16 14 0.0% 0.4 1 
32 94 0.0% 1.8 1300  
48 94 0.0% 1.9 4400  
64 95 0.0% 2.1 9300  
80 98 0.5% 2.4 19400  
96 100 0.7% 2.5 24800  
112 99 1.1% 3.1 25500  
New FT 
Chromatography  
Pool  
>90 %  <0.5%  0.8 (ppm)  11500 (ppm)  
ChromaSorb
TM
 
membrane 
adsorber 
>90 %  <0.5%  NA  60  
Fractogel
® 
media 
TMAE 
>90 % <0.5% NA 200 
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Figure 8 is a photograph of a non-reducing SDS-PAGE gel for the three step process, 
including fractions of the CIEX flow-through resin. It can be seen from the gel that the 
crude cell culture (lane-2) contains a wide range of protein species at a dilute 
concentration which is observed from streak of stain and also contains monoclonal 
antibody (apparent MW between 100 and 250 kDa). The protein-A pool (lane 3) shows a 
much cleaner and concentrated protein, but includes a significant amount of aggregates 
shown by the stain above 250 kDa. The FTCEX fractions show a significant removal of 
aggregated species. Whereas the salt strip shows that the aggregates are significantly 
concentrated. The light bands at approximately 25 and 50 kDa in all the samples are 
likely fragments or light and heavy chain of the monoclonal antibody.  
 
 It is important to understand the utility and benefit from a flow-through purification unit 
operation compared to a traditional bind-and-elute unit operation. We have observed that the 
ability to load our prototype resin #4 to about 150 mg/mL with 2% aggregate present. This is 
advantage over traditional bind-and-elute where you are typically limited to around 50 mg/mL 
loading. However, it is important to make sure that the resulting product is similar between the 
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two methods if the FT-operation is truly a functional replacement. We compared Fractogel
® 
SO3 
media performed in bind-and-elute mode verses our FTCEX resin prototype #4 performed in 
flow-through mode. We loaded the Fractogel
®
 SO3 media to 50 mg/mL and prototype #4 to 150 
mg/mL. The feed was a protein A pool and had an initial aggregate concentration of 3.4%. 
Figures 9A and 9B show the bind-and-elute for Fractogel
®
 SO3 media and FTCEX prototype 
#4, respectively. 
 
 
 
 
 
 
 
Figure 9A (above) Fractogel
®
 SO3 media performed in bind-and-elute mode. 
 
 
 
 
 
 
 
Figure 9B (above) FTCEX prototype #4 performed in flow-through mode. 
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Three Step 
Process 
Step Recovery 
(%) 
Aggregate 
(%) 
Leached 
Protein A 
(ppm) 
CHOP 
(ppm) 
Step 1 Protein A Pool 97 3.4 56 600 
Step 2 Fractogel
®
 
SO3 media 
84 0.0 LOQ 232 
Step 3 ChromaSorb
TM 
Membrane 
Adsorber 
99 0.0 LOQ LOQ 
*LOQ = below the limit of quantification 
 
Table 4A:  Three step process with traditional bind-and-elute CEX as intermediate step. 
 
 
 
 
 
Three Step 
Process 
Step Recovery 
(%) 
Aggregate 
(%) 
Leached 
Protein A 
(ppm) 
CHOP 
(ppm) 
Step 1 Protein A Pool 97 3.4 56 600 
Step 2 FTCIEX Pool 
Prototype 4 
87 0.2 0.8 250 
Step 3 ChromaSorb
TM 
Membrane 
Adsorber 
96 0.2 NA 2 
 
Table 4B: Three step process with FT CEX as intermediate step. 
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DISCUSSION 
 
This project successfully characterized a library of resin prototypes to help determine an 
optimal resin design. These novel resins appear to be an effective replacement for traditional 
cation-exchange resins. The over-arching goal towards a completely flow-through monoclonal 
antibody polishing platform is now closer to becoming a reality.  
The data from the results section strongly suggests that the most efficient resin beads 
used during the cation-exchange process was Resin prototype 4. As seen in Figure 6, Prototype 
#4 displayed the best ability to separate aggregate from monomer, as evidenced by the late 
aggregate break-through (purple dotted line) of the aggregates at 150 mg/mL.  
As seen from figure 7 the resins are relatively insensitive to flow rate from 1-6 minute 
residence time. However, there is about 40 mg/mL difference in break through capacity between 
1 and 6 minute residence time. This can be explained by the decreased contact time at 1 minute, 
which likely does not allow the aggregate to diffuse as far into the resin as the longer residence 
times. However, there is still significant capacity for aggregates at 1 minute residence time, and 
this is likely the most aggressive the flow rate would be challenged. 
Results for the three step process, Table 3, produced a final pool with less than 0.5% 
aggregates, no detectable leached Protein-A, and low levels of HCP, while retaining high 
monoclonal antibody recovery. This is encouraging because this was considered an exceptionally 
challenging feed due to the unusual high levels of HCP in the load material. The increase in 
impurity and removal of aggregates was confirmed by SDS-PAGE.  
It was also important to understand the performance in relation to a more traditional 3-
step process that uses bind-and-elute cation exchange chromatography as an intermediate 
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polishing step. Our new method was loaded to 3X the capacity for traditional CIEX, 150 mg/mL 
compared to 50 mg/mL. The difference is due to the fact that traditional CIEX needs to bind both 
the aggregate and the monomer and additional loading would cause loss in yield due to 
breakthrough of product. The results were very promising for the new method which resulted in 
similar product yield and product quality. The advantage of the new method is primarily due to 
the higher loading which requires less resin to process the same mass of monoclonal antibody. 
This also results in less consumption of buffer due to smaller required column volumes of resin. 
These process intensifications (reduced materials and labor) could product substantial cost 
savings and more attractive process economics.  
An interesting find is that these resins displayed ideal performance under the conditions 
of pH 5 (data not shown) with a residence time of 1-6 minutes. As studies are continued, these 
conditions will be more closely observed for more of the resins that will be characterized and 
categorized. Additionally, another experiment to use in the future would be to use high-through 
put screening on each resin to determine the optimal pH and salt concentration in order to 
remove the maximum amount of aggregates while recovering 80-90% of the monomer which is 
generally considered acceptable.  Additional future experiments might include measuring the 
affinity of the purified mAb for its target to make sure it remains unaltered. 
With these experiments, a successful method of unique flow-through chromatography as 
an efficient way of removing aggregates and other impurities, yielding a purified monoclonal 
antibody concentrate, has been developed. These findings are important in the quest towards 
determining the optimal conditions and matrix structure for potential commercial 
implementation. The next step towards achieving this goal is to add depth to the applications 
knowledge base of this promising technology.   
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